Highlight any text to annotate

Patient-Focused Impact Assessment Act of 2016 (Sec. 2) This bill amends the Federal Food, Drug, and Cosmetic Act to require the Food and Drug Administration (FDA), after approving an application for a new medication, to publish a brief statement on any patient experience data or related information that was part of the application. Patient experience data is information about the impact of a medical condition or a related therapy on a patient's life and the patient's preferences for treatment. (Sec. 3) The FDA must issue guidance on the collection of patient experience data and the use of that data in drug development. (Sec. 4) The Paperwork Reduction Act does not apply to voluntary collection of patient experience data. (Sec. 5) The FDA must report on its review of patient experience data as part of approving applications for new medications.

Add a comment

Sign in to comment on this bill.

Annotate the text

Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.